NASDAQ : CNTA
Centessa Pharmaceuticals plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 40.5 USD (At close: Jun 23, 2026) · Market cap 6.27B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.27B |
| Enterprise Value | 6.11B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 154.73M |
| Shares Change (YoY) | +14.73% |
| Shares Change (QoQ) | +8.15% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 58.21% |
| Float | 92.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.86 |
| P/TBV Ratio | 12.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.53 |
| Quick Ratio | 9.27 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -57.38% |
| Return on Assets (ROA) | -27.43% |
| Return on Invested Capital (ROIC) | -28.90% |
| Return on Capital Employed (ROCE) | -42.41% |
| Weighted Average Cost of Capital (WACC) | 10.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.94M |
| Employee Count | 129 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.27M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +225.83% |
| 50-Day Moving Average | 39.69 |
| 200-Day Moving Average | 29.21 |
| Relative Strength Index (RSI) | 78.18 |
| Average Volume (20 Days) | 2,226,597 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.57M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 1.96% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.18 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -256.69M |
| Pretax Income | -249.37M |
| Net Income | -250.64M |
| EBITDA | -256.35M |
| EBIT | -256.69M |
| Earnings Per Share (EPS) | -$1.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 276.59M |
| Total Debt | 118.56M |
| Net Cash | 158.03M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | 487.35M |
| Book Value Per Share | 3.15 |
| Working Capital | 312.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -208.80M |
| Capital Expenditures | -371,000 |
| Depreciation & Amortization | 343,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -209.17M |
| FCF Per Share | -$1.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.73% |
| Shareholder Yield | -14.73% |
| Earnings Yield | -4.00% |
| FCF Yield | -3.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $44.17 |
| Price Target Difference | 9.06% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 151.10% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.55 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |